Skip to main content

Table 2 Clinical and sexual parameters of subjects with PE + DM and normal group based on Androgen receptor (CAG)n repeats

From: Longer trinucleotide repeats of androgen receptor are associated with higher testosterone and low oxytocin levels in diabetic premature ejaculatory dysfunction patients

Subjects with PE + DM n = 250

Control subjects n = 150

 

CAG Long stretches ( ≥ 26) n = 108

CAG Medium stretches (22–25) n = 88

CAG short stretches ( ≤ 21) n = 54

Kruskal-Wallis = P*

CAG Long stretches ( ≥ 26) n = 43

CAG Medium stretches (22–25) n = 85

CAG short stretches ( ≤ 21) n = 22

Clinical Parameter

 Age (years)

45 (35–55)

43.5 (32–58)

45 (30–60)

NS

45 (30–60)

46 (32–60)

45 (30–60)

 BMI (Kg/m2)

31 (30–32)

31.6 (29.3–33.9)

32.05 (30.1–34.0)

NS

31.1 (28.6–33.6)

31.3 (28.9–33.7)

31.9 (28.85–35.01)

 Blood Sampling Time (8–10 Am)

9.00 (8.00–10)

8.65 (8.00–9.30)

8.72 (8.15–9.30)

NS

9.50 (9.00–10)

9.57 (9.15–10)

8.80 (8.30–9.30)

 Diabetes duration (years)

8.30 (4.5–12.1)

7.85(2.2–13.5)

9.67 (6.37–12.98)

NS

9.3 (4.21–14.56)

8.4 (4.4–12.5)

7.5 (3.3–11.8)

 HbA1C (%)

6.95 (6–7.9)

6.95 (5.9–8.00)

7.1 (6.1–8.1)

< 0.0001

3.8 (3.2–4.5)

3.7 (3.1–4.3)

3.9 (3.3–4.6)

Hormonal Assays

 Oxytocin (pg/ml)

62.9(43.1–82.8)

89.9 (69.9–99.8)

114.2 (99–129.5)

< 0.0001

70.12 (58.1–82.1)

68.85 (56.4–81.3)

69.18 (57.1–81.2)

 Prolactin (ng/ml)

3.01 (2.3–4.8)

5.23 (4.01–6.46)

6.89 (4.7–8.01)

< 0.0001

7.12 (5.98–8.4)

7.03 (5.71–8.40)

7.23 (5.5–8.9)

 Total Testosterone (ng/ml)

6.1 (5.4–6.8)

4.8 (4.4–5.36)

3.4 (3.1–3.8)

< 0.0001

3.9 (3.7–4.1)

3.3 (3.0–3.7)

3.6 (3.1–4.2)

 TSH (mIU/L)

1.53 (1–2.1)

1.6 (1–2.02)

1.6 (1–2.02)

< 0.0001

3.15 (2.5–3.8)

3.15 (2.5–3.8)

3.15 (2.5–3.8)

Premature Ejaculation Assessments

 PEDT

18.8 (17.8–19.8)

18.8 (11.4–26.1)

18.5 (11.2–5.8)

< 0.0001

7.02 (5.1–9.0)

7.23 (5.4–9.0)

7.4 (6.2–8.6)

 Self-estimated IELT (s)

100 (25–175) #

114 (40–188) #

119 (59–179)

< 0.0001

315 (190–440)

317 (125–510)

314 (188–440)

Depression Assessments

 BDI-II

45 (35–55) #

48 (38–58) #

51 (42–60)

< 0.0001

8.75 (4.5–13)

8.7 (4.4–13)

8.75 (4.5–13)

Sexual Assessments

 EF

19 (18–20)

19.5 (17–22)

29.5 (29–30)

NS

26.5 (26–27)

27 (26–28)

26.5 (26–27)

 OR

5 (3–6)

5 (1–9)

5 (1–9)

NS

5 (3–7)

5 (3–7)

6 (3–9)

 SD

4 (2–6)

6 (4–8)

6 (4–8)

NS

5.5 (3–8)

5 (1–9)

6 (4–8)

 OS

4(2–6)

4.5 (3–6)

6.5 (5–8)

NS

5 (4–6)

6 (4–8)

4.5 (3–6)

 IS

2 (1–3)

3 (1–5)

2 (1–3)

< 0.0001

6 (4–8)

7 (6–8)

6 (3–9)

 IIEF-15- Score

34 (26–41)

38 (26–58)

49 (33–58)

< 0.0001

48 (40–56)

50 (40–60)

49 (39–59)

  1. PE Premature Ejaculatory dysfunction; DM Diabetes mellitus type II BMI Body mass index; TSH Thyroid stimulating hormone; PEDT Premature ejaculation diagnostic tool; IELT Intravaginal ejaculatory latency time; BDI-II Beck’s Depression Inventory II; EF Erectile function; OR Orgasmic function; SD Sexual desire; OS Overall satisfaction; IS Intercourse satisfaction; IIEF-15 International index of Erectile Dysfunction-15. Kruskal-Wallis test was used to assess the distribution of values across the subgroups based on the length of CAG repeats
  2. Data are presented as median (interquartile range). Significant differences among PE + DM subgroups are shown in bold (P < 0.001). # (P < 0.05) shows that a result is significantly different from only one of the other PE + DM subgroups. *p < 0.0167 (Kruskal-Wallis/two tailed test with Bonferroni correction) means differences between PE + DM subgroups and entire control group. No statistical difference was found between 3 subgroups (the short, medium, and long CAG) of controls
Back to article page

Basic and Clinical Andrology

ISSN: 2051-4190